Navigation Links
Phase I/II-data on Systemic Application of the TGF-beta2-inhibitor,AP 12009 to be Presented

REGENSBURG, Germany, May 10th, 2007 - Antisense Pharma today announced, that the abstract entitled “Preliminary Results of a Phase I/II-Study in Pancreatic Carcinoma, Malignant Melanoma, and Colorectal Carcinoma with the TGF-beta2 Inhibitor AP 12009” has been selected for poster presentation at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO), which will be held in Chicago, Illinois, U.S.A, from June 1st - 5th.

In the Phase I/II-trial the antisense drug AP 12009 is administered intravenously in patients with either pancreatic carcinoma (stage IVA/IVB), metastatic melanoma (stage III/IV), or advanced colorectal carcinoma (stage III/IV) as a 7-day continuous infusion every other week. “The first milestone of the study has been achieved, as the maximum tolerated dose was determined with this treatment schedule”, explains Hubert Heinrichs, M.D., Ph.D., Chief Medical Officer at Antisense Pharma. Patient recruitment is still ongoing in study sites in Germany as further dose escalations with a modified dosing schedule are now performed. The design of the study, first efficacy and safety data will be presented at the poster presentation (Poster Board No. AA5, Abstract ID 4607) on June 4th 2007 from 8:00 a.m. to 12:00 p.m. in the session “Gastrointestinal (Noncolorectal) Cancer”. Prof. Thomas Seufferlein, Vice Head of the Department of Internal Medicine at the University of Ulm and Principal Investigator of the Phase I/II-Study will be available for questions from 11:00 a.m. to 12:00 p.m. at the poster in Hall A2 on Level 3 of McCormick Place South Building.

About Antisense Pharma

Antisense Pharma is a biopharmaceutical company located in Regensburg, Germany. The company focuses on targeted therapies for malignant tumors and is dedicated to discovering and developing drugs based on antisense technology for worldwide commercialization.

The agents specifically block the synthesis of key cancer proteins. The lead product AP 12009 is targeting Transforming Growth Factor-beta2 (TGF-beta2), a crucial factor that promotes tumor progression via multiple pathomechanisms. AP 12009 is in advanced clinical development for the treatment of high-grade glioma as well as in Phase I/II clinical trial for various other solid tumors. The further product pipeline covers preclinical drug candidates as well as compounds in research and discovery. Antisense Pharma has been honored with the Bavarian Innovation Award and the German Founders Award.

This document contains forward-looking statements with respect to the future business of Antisense Pharma GmbH. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that could occur in the future. There is a number of factors that could cause actual results and developments to differ materially. Antisense Pharma GmbH disclaims any intent of obligation to update any of these forward-looking statements.

For further information please contact:

ANTISENSE PHARMA GmbH

Dr. Heike Specht / Public Relations
Josef-Engert-Str. 9, D-93053 Regensburg
Phone: +49-941-92013-0
Fax: +49-941-92013-29
e-mail: pr@antisense-pharma.com
www.antisense-pharma.com


'"/>




Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... Sept. 18, 2017 EpiVax, Inc. ... bioinformatics and immune engineering, today announced a ... A (H7N9) vaccine. ... seasonal influenza and presents a challenge for ... exposure to be effective. Using state-of-the-art bioinformatics and ...
(Date:9/12/2017)...  ValGenesis Inc., the global leader in Enterprise ... announce the appointment of Dr. Ajaz Hussain ... Directors and Chairman of Advisory Board beginning September ... to manage their entire validation lifecycle process electronically ... process. Furthermore, ValGenesis VLMS enables rigorous compliance, helps ...
(Date:9/7/2017)... Sept. 7, 2017  Eli Lilly and Company ... to streamline operations to more efficiently focus resources ... cost structure. Global workforce reductions, including those from ... to impact approximately 3,500 positions. ... annualized savings of approximately $500 million that will ...
Breaking Medicine Technology:
(Date:9/25/2017)... ... September 25, 2017 , ... “The Ministry of Reconciliation: ... look at the religious stand in the sensitive matter of sexual discrimination, and ... Ministry of Reconciliation: A Compassionate and Realistic Approach to Evangelizing the LGBTQ Community” ...
(Date:9/25/2017)... Ignite Conference (PRWEB) , ... September 25, 2017 , ... ... have teamed up to deliver Netmail’s Hadron Data Auditing and eDiscovery ... Cloud. Netmail will be demo-ing their Hadron solution in a HIPAA/HITRUST Azure Cloud at ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... Workshop, **Presented by FDAnews**, Nov. 1-3, 2017 – Bethesda, MD, http://www.fdanews.com/fdainspectionssummit ... flying colors. And then, on the tenth inspection it failed. , What went ...
(Date:9/24/2017)... ... September 25, 2017 , ... Bhowanie Benimadhu’s new book “ Our ... questions of life and seeks answers in both Eastern and Western religious traditions and ... God is in the mind of humankind for the past thousands of years and ...
(Date:9/24/2017)... , ... September 23, 2017 , ... Throughout the United ... harm. , Every day, physicians, nurses and other providers work to give the ... innovative industry processes. , But U.S. Senators today are threatening to tie our ...
Breaking Medicine News(10 mins):